AstraZeneca pauses £200m investment in Cambridge research site

A picture


The drugmaker AstraZeneca has paused a planned £200m expansion of its Cambridge research site, completing a depressing week for the UK pharmaceutical industry.The decision by the UK’s largest company means none of its much-trumpeted £650m investment package in the UK – which was originally announced in March 2024 – is proceeding.The now stalled £200m Cambridge project had been expected to create 1,000 jobs.In January, AstraZeneca scrapped plans to invest £450m in its vaccine manufacturing facility in Speke, Merseyside, citing a cut in government support, after months of negotiations.An AstraZeneca spokesperson said on Friday: “We constantly reassess the investment needs of our company and can confirm our expansion in Cambridge is paused.

We have no further comment to make.”The latest UK setback contrasts with the company’s moves in other jurisdictions.In July the company announced it would invest $50bn (£37bn) in the US by 2030, as part of a string of pledges by pharmaceutical companies as Donald Trump’s threats to impose sector-specific tariffs loom over the industry.The British drugmaker, which is headquartered in Cambridge, said its US investment would fund a new drug manufacturing facility in Virginia, and expand its laboratories and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas.The news from AstraZeneca caps a week of negative announcements and warnings from a crucial UK industry.

Keir Starmer’s government has described life sciences as “one of the crown jewels of the UK economy”, while the previous Conservative government had vowed to turn the country into a “global science and technology superpower” by 2030,Yet on Wednesday, the US drugmaker Merck, known as MSD in Europe, scrapped a £1bn London research centre as well as laying off 125 scientists in the capital this year,Its planned new lab, called the UK Discovery Centre, opposite St Pancras and King’s Cross stations was already under construction and scheduled to open in two years’ time,It had been expected to employ about 800 people,A day later, Sir John Bell, a prominent scientist and former regius professor of medicine at the University of Oxford, warned that other big pharmaceutical companies were going to stop investing in the UK.

He told BBC Radio 4 he had spoken to several chief executives of large pharmaceutical companies in the past six months “and they’re all in the same space, and that is, they’re not going to do any more investing in the UK”.Then on Friday, Paul Naish, the UK head of market access for the French pharmaceuticals company Sanofi, told the Guardian Britain needed a “proper plan from the Treasury” for life sciences, arguing the country had become “not a good place” to develop or sell drugs.Sign up to Business TodayGet set for the working day – we'll point you to all the business news and analysis you need every morningafter newsletter promotionSanofi said: “Any substantial inward investment into the UK is currently on pause until we see tangible progress towards making the life sciences environment internationally competitive.”Also this week, Eli Lilly, a US drugmaker, said its planned London gateway lab, an incubator space for new drugs that brings together researchers, part of a £279m investment, was on hold.The pharmaceutical industry has long argued that the UK needs to spend more on new medicines, bringing the NHS’s outlay on medications more in line with other countries.

A row between the sector and the health secretary, Wes Streeting, intensified after long-running NHS pricing negotiations broke down without an agreement in late August,Officials at the department of health, concerned after MSD’s move to pull out of research in the UK, reportedly want to reopen those talks,The Association of the British Pharmaceutical Industry wants the clawback rate – at which drugmakers pay back a chunk of their UK revenues to the NHS – reduced from nearly 23% to single digits, similar to levels in other European countries,The best public interest journalism relies on first-hand accounts from people in the know,If you have something to share on this subject you can contact the Business team confidentially using the following methods.

Secure Messaging in the Guardian appThe Guardian app has a tool to send tips about stories.Messages are end to end encrypted and concealed within the routine activity that every Guardian mobile app performs.This prevents an observer from knowing that you are communicating with us at all, let alone what is being said.If you don't already have the Guardian app, download it (iOS/Android) and go to the menu.Scroll down and click on Secure Messaging.

When asked who you wish to contact please select the Guardian Business team,SecureDrop, instant messengers, email, telephone and postIf you can safely use the tor network without being observed or monitored you can send messages and documents to the Guardian via our SecureDrop platform,Finally, our guide at theguardian,com/tips lists several ways to contact us securely, and discusses the pros and cons of each,
businessSee all
A picture

Pound dips after UK economy doesn’t grow in July; Ocado shares slide 20% amid robotic warehouses demand fears – as it happened

The pound has weakened since today’s GDP report showed the UK economy failed to grow in July.Sterling is down 0.2% at $1.355 against the US dollar this morning.Kathleen Brooks, research director at XTB, points out there is “not much to like” from the July monthly GDP update, with zero growth in the economy at the start of the third quarter

A picture

Barclays boss urges UK ministers to limit public sector pay rises

The chief executive of Barclays has said the UK government needs to limit pay rises for public sector workers and resist a further “squeeze” on banks with tax increases.CS Venkatakrishnan said the government needed to look at its own spending levels as the chancellor, Rachel Reeves, seeks ways to address a fiscal hole when she announces her budget in November.“We need to curb expenditure at the government level,” he told the Financial Times. “We need to find a way to curb wage inflation.”Venkatakrishnan said that while the government needed to restrict rising “public sector” wages, the inflationary impact of pay rises was an issue across the UK economy

A picture

UK economy flatlines in July in grim news for Rachel Reeves

The UK economy flatlined in July, according to official figures, in grim news for Rachel Reeves as she gears up for a challenging budget.It was a slowdown compared with June, when the economy grew by 0.4%, according to the Office for National Statistics.GDP expanded strongly in the first half of the year, making the UK the fastest-growing economy in the G7, but it had been widely expected to slow in the second half.The ONS said that growth in the services and construction sectors in July was offset by a 0

A picture

Stagnant GDP shows scale of challenge for Rachel Reeves at autumn budget

“Our economy isn’t broken, but it does feel stuck,” is the message from Rachel Reeves.Having made rebooting the economy the No 1 priority for government, it is a brutally honest assessment from a chancellor more than a year into the job.The latest GDP figures, released on Friday, highlight the scale of the challenge for Reeves at her autumn budget. Growth flatlined in July, slowing from 0.4% in June, as the economy struggled for momentum over the summer

A picture

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

A senior pharmaceuticals executive has called on the government to come up with a “proper” roadmap for raising spending on new medicines, saying Britain is “not a good place” to develop or sell drugs.Paul Naish, the UK head of market access for the French company Sanofi, said Britain was “at a critical point”.He added: “We’ve still got the best universities, we’ve got some of the best scientists in the world, but it’s not a good place to do the development work for medicines. It’s an expensive place to operate, and it’s a terrible place to sell medicines.”The drugmaker MSD, known as Merck in the US, this week ditched its under-construction £1bn research centre in London

A picture

Business rates rise would put hundreds of big shops at risk, say UK retailers

Up to 400 large shops are at risk of closure with as many as 100,000 jobs at risk if the government goes ahead with plans to hit stores with higher business rates, retailers have warned.Some of the UK’s largest retail premises, including supermarkets and department stores, would face higher property tax charges under new rules being considered by the government before November’s budget.The higher charges for larger sites, including warehouses, offices and other premises, are intended to pay for discounts for smaller business properties, such as independent retailers, cafes and pubs, after the Labour government pledged to make the business rates system fairer.The bosses of big retailers including John Lewis, Lidl and B&Q met the chancellor, Rachel Reeves, last week to ask her to exclude retail from the surcharge.The new rules are targeted at all business premises with a rateable value – a figure linked to rents – of more than £500,000